Last $22.90 USD
Change Today +0.67 / 3.01%
Volume 41.0K
OCUL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

ocular therapeutix inc (OCUL) Snapshot

Open
$22.18
Previous Close
$22.23
Day High
$23.96
Day Low
$22.18
52 Week High
12/23/14 - $24.21
52 Week Low
07/31/14 - $11.90
Market Cap
488.3M
Average Volume 10 Days
85.3K
EPS TTM
--
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCULAR THERAPEUTIX INC (OCUL)

Related News

No related news articles were found.

ocular therapeutix inc (OCUL) Related Businessweek News

No Related Businessweek News Found

ocular therapeutix inc (OCUL) Details

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology for treating eye diseases and conditions. The company offers ReSure Sealant, a synthetic ocular sealant in sealing clear corneal incisions following cataract surgery. Its products also include Dexamethasone Punctum Plug, a drug-eluting punctum plug; Travoprost Punctum Plug or the treatment of glaucoma and ocular hypertension; Moxifloxacin Punctum Plug for the treatment of bacterial conjunctivitis; and posterior segment injections. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

52 Employees
Last Reported Date: 07/25/14
Founded in 2006

ocular therapeutix inc (OCUL) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $254.9K
Chief Operating Officer
Total Annual Compensation: $362.5K
Executive Vice President of Clinical, Regulat...
Total Annual Compensation: $321.5K
Compensation as of Fiscal Year 2013.

ocular therapeutix inc (OCUL) Key Developments

Ocular Therapeutix, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 03:20 PM

Ocular Therapeutix, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 03:20 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Amarpreet Sawhney, Founder, Chairman, Chief Executive Officer and President.

Ocular Therapeutix, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Ocular Therapeutix, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company announced revenue of $143,000. Loss from operations was $6,776,000 compared to $3,435,000 for the same period a year ago. Net loss and comprehensive loss was $7,294,000 compared to $3,522,000 for the same period a year ago. Net loss attributable to common stockholders was $7,294,000 compared to $3,527,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.48 compared to $1.34 for the same period a year ago. For the nine months, the company announced revenue of $267,000. Loss from operations was $19,547,000 compared to $9,484,000 for the same period a year ago. Net loss and comprehensive loss was $20,694,000 compared to $9,812,000 for the same period a year ago. Net loss attributable to common stockholders was $20,705,000 compared to $9,834,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $2.93 compared to $3.79 for the same period a year ago.

Ocular Therapeutix, Inc. Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension

Ocular Therapeutix, Inc. announced enrollment of the first patients in a Phase 2b clinical trial evaluating Sustained Release Travoprost (OTX-TP) for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. OTX-TP is administered by a physician as an insert into the punctum, a natural opening in the eyelid near the tear ducts, designed to deliver travoprost to the ocular surface for up to 90 days. The prospective, multicenter, randomized, double-masked, parallel-arm, active controlled study is designed to evaluate 80 patients at 10 clinical sites for the safety and efficacy of the OTX-TP as compared to timolol. Study efficacy endpoints include difference in the mean intraocular pressure change between the treatment groups from baseline at multiple timepoints throughout the study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCUL:US $22.90 USD +0.67

OCUL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCUL.
View Industry Companies
 

Industry Analysis

OCUL

Industry Average

Valuation OCUL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,263.8x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,418.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULAR THERAPEUTIX INC, please visit www.ocutx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.